Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Dexcom Inc (NASDAQ: DXCM) closed the day trading at $80.62 down -1.29% from the previous closing price of $81.67. In other words, the price has decreased by -$1.29 from its previous closing price. On the day, 3.43 million shares were traded. DXCM stock price reached its highest trading level at $81.93 during the session, while it also had its lowest trading level at $79.84.
Ratios:
For a better understanding of DXCM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 55.39. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.52. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 0.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Argus on August 21, 2025, initiated with a Buy rating and assigned the stock a target price of $100.
On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $102.
On May 30, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $104.Goldman initiated its Buy rating on May 30, 2025, with a $104 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’25 when Brown Michael Jon sold 500 shares for $80.29 per share. The transaction valued at 40,145 led to the insider holds 94,102 shares of the business.
FOLETTA MARK G sold 2,750 shares of DXCM for $222,903 on Aug 15 ’25. The Director now owns 51,121 shares after completing the transaction at $81.06 per share. On Aug 15 ’25, another insider, MICHAEL BROWN, who serves as the Officer of the company, bought 500 shares for $80.29 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 31615537152 and an Enterprise Value of 31265556480. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 56.44, and their Forward P/E ratio for the next fiscal year is 31.10. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.35 while its Price-to-Book (P/B) ratio in mrq is 12.29. Its current Enterprise Value per Revenue stands at 7.27 whereas that against EBITDA is 33.863.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.49, which has changed by 0.08842981 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $93.25, while it has fallen to a 52-week low of $57.52. The 50-Day Moving Average of the stock is -2.70%, while the 200-Day Moving Average is calculated to be 1.17%.
Shares Statistics:
Over the past 3-months, DXCM traded about 3.41M shares per day on average, while over the past 10 days, DXCM traded about 3279120 shares per day. A total of 392.20M shares are outstanding, with a floating share count of 386.79M. Insiders hold about 1.37% of the company’s shares, while institutions hold 93.78% stake in the company. Shares short for DXCM as of 1753920000 were 8486867 with a Short Ratio of 2.49, compared to 1751241600 on 10514753. Therefore, it implies a Short% of Shares Outstanding of 8486867 and a Short% of Float of 2.77.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 23.0 analysts. The consensus estimate for the next quarter is $0.68, with high estimates of $0.74 and low estimates of $0.63.
Analysts are recommending an EPS of between $2.15 and $1.91 for the fiscal current year, implying an average EPS of $2.05. EPS for the following year is $2.57, with 25.0 analysts recommending between $2.91 and $2.3.
Revenue Estimates
22 analysts predict $1.18B in revenue for the current quarter. It ranges from a high estimate of $1.21B to a low estimate of $1.15B. As of the current estimate, Dexcom Inc’s year-ago sales were $994.2MFor the next quarter, 22 analysts are estimating revenue of $1.25B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.23B.
A total of 25 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.68B, while the lowest revenue estimate was $4.61B, resulting in an average revenue estimate of $4.62B. In the same quarter a year ago, actual revenue was $4.03BBased on 25 analysts’ estimates, the company’s revenue will be $5.34B in the next fiscal year. The high estimate is $5.65B and the low estimate is $5.1B.
